HIGHLIGHTS
- who: Pei-Pei Wang and collaborators from the Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life and Medicine, University of Science and Technology of China, Hefei, China have published the article: BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies, in the Journal: Cancers 2022, 14, 4067. of /2022/
- what: The aim of this study was to determine the maximum tolerated dose (MTD) or recommended dose for phase II clinical trials, which was found to be 200 mg encorafenib and 300 mg alpelisib.
SUMMARY
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.